Takeda gets EU approval for Fruzaqla for colorectal cancer (NYSE:TAK)
2024-06-21
jetcityimage/iStock Editorial via Getty Images Takeda (NYSE:TAK) has received EU regulatory approval for Fruzaqla for the treatment of patients with metastatic colorectal cancer who have been previously treatmed with standard therapies and who have progressed while on or are intolerant of treatment with trifluridine-tipiracil or regorafenib. The approval follows aContinue Reading